These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 37273167)

  • 1. Tecovirimat for the treatment of severe Mpox in Germany.
    Hermanussen L; Brehm TT; Wolf T; Boesecke C; Schlabe S; Borgans F; Monin MB; Jensen BO; Windhaber S; Scholten S; Jordan S; Lütgehetmann M; Wiesch JSZ; Addo MM; Mikolajewska A; Niebank M; Schmiedel S
    Infection; 2023 Oct; 51(5):1563-1568. PubMed ID: 37273167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tecovirimat Treatment of People With HIV During the 2022 Mpox Outbreak : A Retrospective Cohort Study.
    McLean J; Stoeckle K; Huang S; Berardi J; Gray B; Glesby MJ; Zucker J
    Ann Intern Med; 2023 May; 176(5):642-648. PubMed ID: 37126820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics.
    Candela C; Raccagni AR; Bruzzesi E; Bertoni C; Rizzo A; Gagliardi G; Canetti D; Gianotti N; Mileto D; Gismondo MR; Castagna A; Nozza S;
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Tecovirimat Treatment for Mpox Disease Among People With HIV.
    Aldred B; Lyles RH; Scott JY; Gromer DJ; Aldredge A; Workowski KA; Wiley Z; Titanji BK; Szabo B; Sheth AN; Rebolledo PA; Nguyen ML; Marconi VC; Kelley CF; Kandiah S; Kalapila A; Jacob JT; Hall B; Colasanti JA; Cartwright EJ; Cantos VD
    JAMA Intern Med; 2024 Mar; 184(3):275-279. PubMed ID: 38190312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus.
    Chenchula S; Ghanta MK; Amerneni KC; Rajakarunakaran P; Chandra MB; Chavan M; Gupta R
    Arch Virol; 2023 Jun; 168(7):195. PubMed ID: 37386209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol - United States, May-August 2022.
    O'Laughlin K; Tobolowsky FA; Elmor R; Overton R; O'Connor SM; Damon IK; Petersen BW; Rao AK; Chatham-Stephens K; Yu P; Yu Y;
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1190-1195. PubMed ID: 36107794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022.
    Contag CA; Mische L; Fong I; Karan A; Vaidya A; McCormick DW; Bower W; Hacker JK; Johnson K; SanJuan P; Crebbin L; Temmins C; Sahni H; Bogler Y; Cooper JD; Narasimhan S
    Emerg Infect Dis; 2023 Dec; 29(12):2520-2523. PubMed ID: 37856215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharyngo-tonsillar involvement of Mpox in a cohort of men who have sex with men (MSM): A serious risk of missing diagnosis.
    Pinnetti C; Mondi A; Mazzotta V; Vita S; Carletti F; Aguglia C; Beccacece A; Vergori A; Gagliardini R; Specchiarello E; Ascoli Bartoli T; Baldini F; Giancola ML; Valli MB; D'Abramo A; Gebremeskel Teklè S; Fontana C; Garbuglia AR; Girardi E; Maggi F; Vaia F; Nicastri E; Antinori A
    J Infect Public Health; 2024 Jan; 17(1):130-136. PubMed ID: 38000313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mpox in the New York metropolitan area, Summer 2022.
    Gnanaprakasam R; Keller M; Glassman R; El-Khoury MY; Chen DS; Feola N; Feldman J; Chaturvedi V
    J Med Virol; 2023 Apr; 95(4):e28699. PubMed ID: 36951318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim Clinical Treatment Considerations for Severe Manifestations of Mpox - United States, February 2023.
    Rao AK; Schrodt CA; Minhaj FS; Waltenburg MA; Cash-Goldwasser S; Yu Y; Petersen BW; Hutson C; Damon IK
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(9):232-243. PubMed ID: 36862595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mpox in people with advanced HIV infection: a global case series.
    Mitjà O; Alemany A; Marks M; Lezama Mora JI; Rodríguez-Aldama JC; Torres Silva MS; Corral Herrera EA; Crabtree-Ramirez B; Blanco JL; Girometti N; Mazzotta V; Hazra A; Silva M; Montenegro-Idrogo JJ; Gebo K; Ghosn J; Peña Vázquez MF; Matos Prado E; Unigwe U; Villar-García J; Wald-Dickler N; Zucker J; Paredes R; Calmy A; Waters L; Galvan-Casas C; Walmsley S; Orkin CM;
    Lancet; 2023 Mar; 401(10380):939-949. PubMed ID: 36828001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mpox in people with past infection or a complete vaccination course: a global case series.
    Hazra A; Zucker J; Bell E; Flores J; Gordon L; Mitjà O; Suñer C; Lemaignen A; Jamard S; Nozza S; Nori AV; Pérez-Barragán E; Rodríguez-Aldama JC; Blanco JL; Delaugerre C; Turner D; Fuertes I; Leiro V; Walmsley SL; Orkin CM;
    Lancet Infect Dis; 2024 Jan; 24(1):57-64. PubMed ID: 37678309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A plague passing over: Clinical features of the 2022 mpox outbreak in patients of color living with HIV.
    Momin ZK; Lee A; Vandergriff TW; Bowling JE; Chamseddin B; Dominguez A; Hosler GA; Wang RC; Kitchell E
    HIV Med; 2023 Oct; 24(10):1056-1065. PubMed ID: 37336551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat.
    Nunes DDS; Higa LM; Oliveira RL; da Costa LC; Bomfim LM; Gonçalves CCA; Mariani D; Hruby DE; Voloch CM; Castiñeiras TMPP; Tanuri A; Damaso CR
    Mem Inst Oswaldo Cruz; 2023; 118():e230056. PubMed ID: 37436275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
    Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
    Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of clinical course of Mpox among HIV-negative and HIV-positive patients: A 2022 cohort of hospitalized patients in Central Europe.
    Kowalski J; Cielniak I; Garbacz-Łagożna E; Cholewińska-Szymańska G; Parczewski M
    J Med Virol; 2023 Oct; 95(10):e29172. PubMed ID: 37861345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany.
    Hoffmann C; Jessen H; Wyen C; Grunwald S; Noe S; Teichmann J; Krauss AS; Kolarikal H; Scholten S; Schuler C; Bickel M; Roll C; Kreckel P; Köppe S; Straub M; Klausen G; Lenz J; Esser S; Jensen B; Rausch M; Unger S; Pauli R; Härter G; Müller M; Masuhr A; Schäfer G; Seybold U; Schellberg S; Schneider J; Monin MB; Wolf E; Spinner CD; Boesecke C
    HIV Med; 2023 Apr; 24(4):389-397. PubMed ID: 36059149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and viral dynamics of tecovirimat in patients with MPOX: A multicenter open-label, double-arm trial in Japan.
    Akiyama Y; Morioka S; Tsuzuki S; Yoshikawa T; Yamato M; Nakamura H; Shimojima M; Takakusaki M; Saito S; Takahashi K; Sanada M; Komatsubara M; Takebuchi K; Yamaguchi E; Suzuki T; Shimokawa K; Kurosu T; Kawahara M; Oishi K; Ebihara H; Ohmagari N
    J Infect Chemother; 2024 Jun; 30(6):488-493. PubMed ID: 38042298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of tecovirimat in subjects with Mpox.
    Tempestilli M; Mondi A; D'Avolio A; Forini O; Pinnetti C; Mazzotta V; Gagliardini R; Beccacece A; De Nicolò A; Faccendini P; Cimini E; Maggi F; Girardi E; Nicastri E; Boffito M; Vaia F; Antinori A
    Int J Antimicrob Agents; 2024 Feb; 63(2):107068. PubMed ID: 38141836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of mpox positive, versus mpox negative, and mpox unsuspected clients from the Centre of Sexual Health, Public Health Service of Amsterdam, 20 May to 15 September 2022.
    Siegenbeek van Heukelom ML; Jongen VW; Schouten J; Hoornenborg E; Bruisten S; Westerhuis B; Welkers MR; Vergunst CE; Prins M; Schim van der Loeff MF; de Vries HJC
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1891-1896. PubMed ID: 37212540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.